Drug
Cabozantinib
Cabozantinib: highest development phase Post-Market, developed by Bristol-Myers Squibb, Endo, Exelixis and others. 34 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Bristol-Myers Squibb, Endo, Exelixis
Trials
| Drug | Phase | Indication |
|---|---|---|
| Cabozantinib (XL184) 140 mg NCT01896479 | Post-Market | Medullary Thyroid Cancer |
| Cabozantinib NCT03937219 | Phase 3 | Renal Cell Carcinoma |
| cabozantinib NCT01522443 | Phase 3 | Prostate Cancer |
| Cabozantinib NCT03690388 | Phase 3 | Differentiated Thyroid Cancer |
| Cabozantinib NCT07620574 | Phase 3 | Cancer |
| Cabozantinib NCT03945773 | Phase 2 | Locally Advanced or Metastatic Renal Cell Carcinoma |
| Cabozantinib NCT05660954 | Phase 2 | Differentiated Thyroid Cancer |
| Cabozantinib NCT04322955 | Phase 2 | Kidney Cancer |
| Cabozantinib 20 MG NCT04131543 | Phase 2 | Non Small Cell Lung Cancer |
| Cabozantinib 80 MG NCT05931393 | Phase 2 | RCC |
| Cabozantinib NCT04631744 | Phase 2 | Prostate Cancer |
| Cabozantinib NCT04413123 | Phase 2 | Papillary Renal Cell Carcinoma |
| Cabozantinib NCT04963283 | Phase 2 | Colorectal Adenocarcinoma |
| cabozantinib NCT01995058 | Phase 2 | Prostate Cancer |
| Cabozantinib NCT05052723 | Phase 2 | Pancreatic Cancer |
| Cabozantinib NCT01954745 | Phase 2 | Bile Duct Cancer |
| Cabozantinib NCT04204850 | Phase 2 | Hepatocellular Carcinoma |
| Cabozantinib NCT05425004 | Phase 2 | Meningioma |
| Cabozantinib NCT03468218 | Phase 2 | Metastatic Head and Neck Carcinoma |
| Cabozantinib NCT04164979 | Phase 2 | Gastric Adenocarcinoma |
| Cabozantinib NCT04551430 | Phase 2 | Metastatic Soft-tissue Sarcoma |
| Cabozantinib NCT06341712 | Phase 2 | Osteosarcoma |
| cabozantinib NCT02132598 | Phase 2 | Non Small Cell Lung Cancer (NSCLC) |
| Cabozantinib NCT01630590 | Phase 2 | Prostate Cancer |
| Cabozantinib NCT03964337 | Phase 2 | Prostate Cancer |
| Cabozantinib NCT05135975 | Phase 2 | Neuroblastoma |
| cabozantinib capsules NCT01553656 | Phase 1 | Solid Tumors |
| Cabozantinib NCT05613894 | Phase 1 | Metastatic Castration-resistant Prostate Cancer |
| cabozantinib NCT01961765 | Phase 1 | Relapsed Acute Myeloid Leukemia |
| Cabozantinib NCT03611595 | Phase 1 | Solid Tumor |
| Cabozantinib NCT04477512 | Phase 1 | Metastatic Hormone Refractory Prostate Cancer |
| cabozantinib NCT01493869 | Phase 1 | Healthy |
| Cabozantinib NCT03299946 | Phase 1 | Locally Advanced Hepatocellular Carcinoma |
| Cabozantinib NCT06132945 | Phase 1 | Metastatic Renal Cell Carcinoma |
Latest
No recent events.
Follow Cabozantinib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.